Dominik Ruttinger
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: October 17, 2025
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Journal: Cancer discovery
Published: May 14, 2025
Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 20, 2023
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Journal: Journal for immunotherapy of cancer
Published: March 08, 2022
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2021
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Journal: Blood advances
Published: March 02, 2021
Deep Learning-based Propensity Scores for Confounding Control in Comparative Effectiveness Research: A Large-scale, Real-world Data Study.
Journal: Epidemiology (Cambridge, Mass.)
Published: February 16, 2021
Prognostic models: clinical impact now within reach.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 01, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
Journal: Journal for immunotherapy of cancer
Published: September 21, 2020
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 29, 2020
PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.
Journal: Clinical pharmacology and therapeutics
Published: April 08, 2020
An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 13, 2020
Last Updated: 09/26/2026